Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
Sign Up to like & getrecommendations! Published in 2020 at "Neuroscience Letters"
DOI: 10.1016/j.neulet.2020.135432
Abstract: Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are chemogenetic tools commonly-used to manipulate brain activity. The most widely-used synthetic DREADD ligand, clozapine-N-oxide (CNO), is back-metabolized to clozapine which can itself activate endogenous receptors. Studies… read more here.
Keywords: dreadd; locomotion; non dreadd; injection ... See more keywords